Skip to main content
. 2021 Aug 31;12:670389. doi: 10.3389/fphar.2021.670389

FIGURE 5.

FIGURE 5

Effects of Sitagliptin on ROS level and cell cycles in PA-treated HUVECs. (A) MTT assay: HUVECs were treated with CON (no PA medium), PA (0.5 mmol/L PA), PA + 20 (PA + 20 μmol/L SIT), PA + 40 (PA + 40 μmol/L SIT), PA + 80 (PA + 80 μmol/L SIT), PA + 160 (PA + 160 μmol/L SIT), and PA + 320 (PA + 320 μmol/L SIT) for 24 h respectively; (B) Assay of ROS level in HUVECs. HUVECs were treated with NC, Rousp, CON (no PA medium), PA, PA + SIT-L (PA + 40 μmol/L SIT); PA + SIT-H (PA + 160 μmol/L SIT); PA + PBA (PA + 10 mmol/L PBA) and TM (1 μg/ml) for 24 h respectively; (C) Quantification of B, values displayed are mean ± SEM from three representative images; (D) Cell proliferation of HUVECs by flow cytometry: HUVECs were treated with CON, PA, PA + SIT-L, PA + SIT-H, PA + PBA and TM for 24 h respectively, values displayed are means ± SEM of three independent experiments. ***p < 0.001 vs. CON group; && p < 0.01, &&& p < 0.001 vs. PA group; % p < 0.05, %%% p < 0.001 vs. SIT-L group.